Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports

Taku Fujimura; Sadanori Furudate; Aya Kakizaki; Yumi Kambayashi; Takahiro Haga; Akira Hashimoto; Setsuya Aiba

doi:10.1111/1346-8138.13229

Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports

Taku Fujimura, Sadanori Furudate, Aya Kakizaki, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Because nivolumab significantly prolongs survival in patients with metastatic melanoma, enhancing its antitumor immune response is of great interest to dermato-oncologists. In this report, we describe two cases of metastatic melanoma successfully treated with nivolumab in combination with contact immunotherapy, using contact sensitizing agents, such as squaric acid dibutylester and diphencyprone. In addition, immunohistochemical staining supported one of the possible mechanisms of this combination therapy. Our present cases suggested a possible therapy for metastatic melanoma using nivolumab in combination with contact immunotherapy.

Original language	English
Pages (from-to)	686-689
Number of pages	4
Journal	Journal of Dermatology
Volume	43
Issue number	6
DOIs	https://doi.org/10.1111/1346-8138.13229
Publication status	Published - 2016 Jun 1

Keywords

Contact immunotherapy
Immunohistochemical staining
Melanoma
Nivolumab
PD-1/PD-L1 blockade

ASJC Scopus subject areas

Dermatology

Access to Document

10.1111/1346-8138.13229

Cite this

@article{16767390b4a547a996aee8bbca79ee76,

title = "Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports",

abstract = "Because nivolumab significantly prolongs survival in patients with metastatic melanoma, enhancing its antitumor immune response is of great interest to dermato-oncologists. In this report, we describe two cases of metastatic melanoma successfully treated with nivolumab in combination with contact immunotherapy, using contact sensitizing agents, such as squaric acid dibutylester and diphencyprone. In addition, immunohistochemical staining supported one of the possible mechanisms of this combination therapy. Our present cases suggested a possible therapy for metastatic melanoma using nivolumab in combination with contact immunotherapy.",

keywords = "Contact immunotherapy, Immunohistochemical staining, Melanoma, Nivolumab, PD-1/PD-L1 blockade",

author = "Taku Fujimura and Sadanori Furudate and Aya Kakizaki and Yumi Kambayashi and Takahiro Haga and Akira Hashimoto and Setsuya Aiba",

note = "Publisher Copyright: {\textcopyright} 2015 Japanese Dermatological Association.",

year = "2016",

month = jun,

day = "1",

doi = "10.1111/1346-8138.13229",

language = "English",

volume = "43",

pages = "686--689",

journal = "Journal of Dermatology",

issn = "0385-2407",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma

T2 - Two cases reports

AU - Fujimura, Taku

AU - Furudate, Sadanori

AU - Kakizaki, Aya

AU - Kambayashi, Yumi

AU - Haga, Takahiro

AU - Hashimoto, Akira

AU - Aiba, Setsuya

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Because nivolumab significantly prolongs survival in patients with metastatic melanoma, enhancing its antitumor immune response is of great interest to dermato-oncologists. In this report, we describe two cases of metastatic melanoma successfully treated with nivolumab in combination with contact immunotherapy, using contact sensitizing agents, such as squaric acid dibutylester and diphencyprone. In addition, immunohistochemical staining supported one of the possible mechanisms of this combination therapy. Our present cases suggested a possible therapy for metastatic melanoma using nivolumab in combination with contact immunotherapy.

AB - Because nivolumab significantly prolongs survival in patients with metastatic melanoma, enhancing its antitumor immune response is of great interest to dermato-oncologists. In this report, we describe two cases of metastatic melanoma successfully treated with nivolumab in combination with contact immunotherapy, using contact sensitizing agents, such as squaric acid dibutylester and diphencyprone. In addition, immunohistochemical staining supported one of the possible mechanisms of this combination therapy. Our present cases suggested a possible therapy for metastatic melanoma using nivolumab in combination with contact immunotherapy.

KW - Contact immunotherapy

KW - Immunohistochemical staining

KW - Melanoma

KW - Nivolumab

KW - PD-1/PD-L1 blockade

UR - http://www.scopus.com/inward/record.url?scp=84949871235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949871235&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.13229

DO - 10.1111/1346-8138.13229

M3 - Article

C2 - 26663262

AN - SCOPUS:84949871235

SN - 0385-2407

VL - 43

SP - 686

EP - 689

JO - Journal of Dermatology

JF - Journal of Dermatology

IS - 6

ER -

Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this